Xu Kang

Title: **Innovator Xu Kang: Pioneering Advances in Eptifibatide Preparation**

Introduction

Xu Kang, an accomplished inventor based in Shenzhen, China, has made notable contributions to the field of biotechnology. His expertise and innovative spirit have led to the development of a unique method for preparing eptifibatide, a synthetic peptide used in medical applications.

Latest Patents

Xu Kang holds a patent for the "Method for preparing eptifibatide." This method includes obtaining an eptifibatide refined peptide solution and subsequently freeze-drying an eptifibatide refined peptide concentrate, which has a concentration of 15-30 mg/ml. The patent outlines specific parameters for rotary evaporation involved in the process, maintaining temperatures between 25°C and 35°C. The preparation process requires coupling cysteine with a resin to achieve a Cys-resin, followed by the gradual coupling of various amino acids to obtain a polypeptide. Finally, the eptifibatide refined peptide solution is produced through oxidation, cleavage, purification, and salt transfer.

Career Highlights

As a key figure at Hybio Pharmaceutical Co., Ltd., Xu Kang has demonstrated leadership and innovation in pharmaceutical research. His work not only contributes to the understanding of peptide synthesis but also increases the accessibility of essential medicinal compounds. Xu's dedication to advancing medical technology ensures a lasting impact in his field.

Collaborations

Throughout his career, Xu Kang has collaborated with esteemed colleagues such as Jian Hua Liu and Yaping Ma. This teamwork fosters an environment of intellectual exchange and innovation, which is critical for successful advancements in the ever-evolving biotechnology sector.

Conclusion

Xu Kang's innovative approach to eptifibatide production showcases his commitment to advancing medical science through invention. His patent reflects a significant step forward, enabling enhanced preparation methods that may have substantial implications for the pharmaceutical industry. As he continues his work at Hybio Pharmaceutical Co., Ltd., the contributions of Xu Kang and his collaborators are likely to lead to further breakthroughs in drug development and therapeutic applications.